# Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

> **NCT01132664** · PHASE1,PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 72 (actual)

## Conditions studied

- Metastatic Breast Cancer
- HER2+ Breast Cancer

## Interventions

- **DRUG:** BKM120
- **DRUG:** Trastuzumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01132664
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 72 (ACTUAL)
- **Why stopped:** Due to the rare patient population and challenges to enroll patients.
- **Last updated:** 2016-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01132664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01132664, "Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01132664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*